Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction

NCT ID: NCT02115230

Last Updated: 2014-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a randomized prospective controlled study of transcatheter renal denervation in patients with Heart Failure With Normal LV Ejection Fraction. The purpose of the study is to evaluate the safety and effectiveness of renal denervation in patients with Heart Failure With Normal LV Ejection Fraction, due to reduction in renal and systemic sympathetic activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Diastolic Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal denervation + medical therapy

Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure

Group Type EXPERIMENTAL

Renal denervation + medical therapy

Intervention Type PROCEDURE

Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure

Medical therapy

Standard optimized medical therapy for diastolic heart failure

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal denervation + medical therapy

Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertension treated with at least 2 antihypertensive drugs;
* Heart failure with a normal LV ejection fraction;
* Left Ventricular Hypertrophy (LV mass index \> 96 g/m2 in women and \> 116 g/m2 in men);
* ≥ 18 years of age;

Exclusion Criteria

* Known secondary cause of hypertension
* Uncontrolled blood pressure (≥ 180x110mmHg)
* Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with balloon or stent
* Advanced renal insufficiency (estimated glomerular filtration rate (GFR) \< 30 ml/min/1.73 square meters)
* Diabetes Mellitus type 1
* Acute coronary syndrome or a cerebrovascular accident in the last 6 months
* Known other cause of respiratory dysfunction
* Previous LV systolic dysfunction (LVEF \< 50%)
* Restrictive cardiomyopathy or Hypertrophic cardiomyopathy
* Significant valvar dysfunction
* Atrial flutter or atrial fibrillation
* Use of the oral anticoagulants
* Drug and Alcohol dependence
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InCor Heart Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pedro A. Lemos

Pedro A. Lemos, Professor of Medicine, InCor Heart Institute

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pedro A Lemos, MD PhD

Role: STUDY_CHAIR

Heart Institute - InCor. University of Sao Paulo Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Institute - InCor. University of Sao Paulo Medical School

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patricia Pereira

Role: primary

+55 11 2661-5368

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IncorRDN-ICFEN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.